Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
Returns on capital
Coeptis Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-69.1%
avg -312.9%
ROIC
-71.7%
avg -103.9%
ROA
-60.1%
avg 124.4%
Analysis
ROA is currently the strongest return metric at -60.1% versus its period average of 124.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David Mehalick | Co-Founder, Chairman of the Board, Chief Executive Officer & President | USD 597K | 57 | 330.19K | 9.40% |
Daniel Alexander Yerace | Co-Founder, Vice President of Operations & Director | USD 452K | 43 | 70.53K | 2.01% |
Brian Cogley | Chief Financial Officer | USD 310.39K | 39 | 22.50K | 0.64% |
Christine Elise Sheehy | Co-Founder, VP of Compliance & Corporate Secretary | USD 75K | 58 | 64.03K | 1.82% |
Compensation is shown in the reported currency; data updated Jun 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 11, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -25.0% (2yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at -25.0% (2yr), giving you a quick read on expected growth from here.
Competitors
Who does Coeptis Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about COEP's management, answered from reported figures.
Who manages COEP?
Coeptis Therapeutics, Inc. (COEP) lists 4 active executives. The top listed executive is Daniel Alexander Yerace, Co-Founder, Vice President of Operations & Director.
Are COEP insiders buying or selling?
Recent insider activity shows net buying of $42.88M.
Continue the stock analysis
Jump to another research area for this company.